Sabra Health Care REIT Reports Strong Q1 Revenue Growth, Increased FFO, and Strategic Portfolio Activity
Summary
Sabra Health Care REIT reported a significant increase in Q1 2026 revenues and FFO per share, driven by strategic acquisitions and active portfolio management, while maintaining a strong liquidity position.
Key Events
-
Strong Revenue Growth
Total revenues increased by 20.8% to $221.8 million in Q1 2026 compared to $183.5 million in Q1 2025.
-
Increased FFO and AFFO Per Share
FFO per diluted common share rose to $0.37 (from $0.36) and AFFO per diluted common share increased to $0.39 (from $0.37) year-over-year.
-
Significant Acquisitions
Acquired three Senior Housing - Managed communities and one skilled nursing facility for an aggregate of $96.1 million during the quarter.
-
Strategic Asset Sales
Subsequent to quarter-end, the company completed the sale of three skilled nursing facilities for an aggregate gross sales price of $79.4 million as part of a capital recycling initiative.
Analysis
Sabra Health Care REIT's first-quarter results demonstrate robust operational performance with a substantial increase in total revenues and key REIT metrics like FFO and AFFO per diluted share. The company actively managed its portfolio through significant acquisitions of senior housing and skilled nursing facilities, alongside the sale of three skilled nursing facilities, indicating a capital recycling initiative to enhance portfolio quality. While GAAP diluted EPS saw a slight decrease due to an increased share count from ATM program utilization, the growth in FFO and AFFO per share is a more relevant indicator for REIT performance and signals underlying business strength. The strong liquidity position and positive regulatory developments, such as the repeal of minimum nurse staffing standards, further support a favorable outlook for the company's operations.
At the time of this filing, SBRA was trading at $20.35 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $17.04 to $21.07. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.